THERAPY DOSSIER · th-664191bce36b

Etazolate

Drug · GABA receptor beta-3 subunit positive allosteric modulator (POSITIVE ALLOSTERIC MODULATOR; direct_interaction true, disease_efficacy true; mec_id 5214)

Not approved Suggest a correction

Evidence & regulatory context

Mechanism: GABA receptor beta-3 subunit positive allosteric modulator (POSITIVE ALLOSTERIC MODULATOR; direct_interaction true, disease_efficacy true; mec_id 5214)
Target: CHEMBL1847
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL356388 ↗
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: Etazolate; EHT-0202; EHT 0202; SQ-20009; Etazolate hydrochloride (CHEMBL1256671); NSC-163611
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00880412 ↗PHASE2completed

Trial title not recorded

Alzheimer's Disease

Enrolment: 197 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23178198 ↗2012Reported benefit

Etazolate, an α-secretase activator, reduces neuroinflammation and offers persistent neuroprotection following traumatic brain injury in mice.

MouseTBIUnspecifiedmale1, 3 or 10 mg/kg2 h after traumatic brain injury

Model: Traumatic brain injury induced by mechanical percussion in mice

A single dose of etazolate produced dose-dependent anti-inflammatory and anti-oedematous effects with lasting memory improvement, reduced locomotor hyperactivity and olfactory bulb tissue protection, associated with restored sAPPα levels.

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…